Analyst firms · Barclays · SRPT

Barclays SRPT price target and rating history

Sarepta Therapeutics Inc. (SRPT) · Health Care

Barclays rates Sarepta Therapeutics Inc. (SRPT) Equal Weight with a $20 price target, as of its latest action on Jan 28, 2026. It has published 4 rating actions on SRPT since July 2025, including 1 upgrade and 2 downgrades. Across 4 firms with a SRPT price target in the last 12 months, the median target is $23.50. Barclays's $20 is 15% below that.

Current rating
Equal Weight
Price target
$20
Median target, all firms
$23.50
Actions on SRPT
4

Barclays price target on SRPT

$22$16$102026
Barclays price target on SRPT, each point a stated target, July 2025 to January 2026.

Every Barclays rating on SRPT

How other firms rate SRPT

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Deutsche BankHold$18Nov 10, 2026
Wolfe ResearchOutperform$27Jul 9, 2026
BarclaysEqual Weight$20Jan 28, 2026
WedbushOutperform$32Dec 9, 2025

Questions about Barclays and SRPT

What is Barclays's price target for SRPT?
Barclays's latest stated price target for Sarepta Therapeutics Inc. (SRPT) is $20, from its action on Jan 28, 2026.
What is Barclays's rating on SRPT?
Barclays rates SRPT Equal Weight, a neutral rating, as of Jan 28, 2026.
When did Barclays last change its view on SRPT?
On Jan 28, 2026, Barclays resumes coverage at Equal Weight, price target $20.
How does Barclays's SRPT target compare with other analysts?
Across 4 firms with a SRPT price target in the last 12 months, the median target is $23.50. Barclays's $20 is 15% below that.

More SRPT rating histories

All Barclays ratingsSRPT news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.